Biogenvs.Gilead Sciences
BIIB vs GILD · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 5.6× larger than Biogen by market cap; year to date, Biogen leads (+24.1% vs +19.8%).
Side by side
| BIIB | GILD | |
|---|---|---|
| Market cap | $32.9B | $186B |
| Price | $225.71 | $151.17 |
| Today | +3.3% | +2.8% |
| Return YTD | +24.1% | +19.8% |
| Return 1Y | +44.7% | +24.4% |
| Since June 26, 2026 | +4.5% | +18.2% |
| P/E | 39.4 | — |
| P/S | 3.3 | 6.1 |
| P/B | 1.7 | 15.7 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →More BIIB & GILD comparisons
Other head-to-heads in the Biotech & innovation segment.
See where BIIB and GILD sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →